氟维司群治疗受体阳性转移性乳腺癌患者的疗效及安全性  

Effect and safety of fulvestrant in the treatment of patients with receptor-positive metastatic breast cancer

作　　者：张彦[1] 王军华[1] 孙红[1] 张忠新[1] 张星霖[1] 韩真真 袁胜利[1] 

机构地区：[1]青岛市市立医院肿瘤科,266000

出　　处：《中国实用医药》2014年第21期1-3,共3页China Practical Medicine

摘　　要：目的探讨氟维司群(FUL)对受体阳性转移性乳腺癌(MBC)患者的疗效及安全性。方法 24例患者接受氟维司群治疗,0、14及28 d各肌内注射250 mg,随后每28天肌内注射250 mg,直至肿瘤进展。主要研究终点为至疾病进展时间(TTP),次要终点为客观有效率(ORR)及临床获益率(CBR)。结果本组24例患者中位TTP为4.4个月,ORR为8.3%(2/24),CBR为25.0%,其中部分缓解(PR)2例,疾病稳定(SD)超过24周4例。氟维司群的疗效与患者术后无病生存期(DFS)及解救治疗线数等因素相关。全组不良反应较轻微。结论氟维司群是治疗MBC患者的有效内分泌治疗药物,安全性较好。Objective To evaluate the effect and safety of fulvestrant in the treatment of patients with receptor-positive metastatic breast cancer（MBC）. Methods Selected 24 patients as research objects. All for fulvestrant： 250 mg/d on 0, 14 th, 28 th day, and 250 mg every 28 days thereafter. The primary endpoint was to find the time to progression（TTP）, secondary endpoints included objective response rate（ORR） and clinical benefit rate（CBR）. Results The median TTP was 4.4 months with an overall response rate of 8.3%, CBR was 25%, including 2 patients who showed a partial response（PR） and 4 patients who achieved stable disease（SD）≥24 weeks. Efficacy of fulvestrant had associated with disease free survival（DFS） and advanced treatment lines. The treatment was well tolerated. Conclusion Fulvestrant is effective and tolerable in the treatment of patients with MBC.

关 键 词：转移性乳腺癌 雌激素受体 氟维司群 

分 类 号：R737.9[医药卫生—肿瘤]